Alvotech (ALVO) Expands With LOTTE As Its Undervalued Narrative Faces A Fresh Test

Alvotech (NasdaqGM:ALVO) is back in focus after a new long term manufacturing agreement with LOTTE Biologics, which expanded its US footprint and global biosimilar supply options for antibody products.

Recent news seems to be arriving into a stock that has already been building momentum. Alvotech’s 90 day share price return of 76.2% and 30 day share price gain of 9.96% sit in sharp contrast to a 1 year total shareholder return that is still down 32.6%. This suggests sentiment has improved lately as investors react to the LOTTE Biologics partnership and the FDA’s fresh sign off on added Reykjavik capacity.

Scan beyond Alvotech’s surge to size up other biosimilar and healthcare manufacturers showing strong momentum and fundamentals with our curated 35 healthcare AI stocks.

Alvotech now trades below both intrinsic estimates and analyst targets despite the recent jump. Is that a reasonable response to past losses and execution risk, or has caution pushed the valuation too far down?

Most Popular Narrative: 14% Undervalued

Against a last close of $5.85, the most followed Alvotech narrative points to a fair value of $6.80, which frames the stock as discounted while still sensitive to execution and regulatory outcomes under an 8.58% discount rate.

Ongoing launch and approval pipeline activity, including upcoming regulatory decisions in major global markets (for AVT03, AVT05, AVT23, and others), positions the company to tap into blockbuster biologic markets coming off patent, potentially driving a step-change in topline revenue once approvals are secured.

See why 14 investors see Alvotech as 14% undervalued.

Result: Fair Value of $6.80 (UNDERVALUED)

Still, the Alvotech story can change quickly if milestone payments arrive later than expected, or if partner concentration issues lead to sudden revenue disruption.

Find out about the key risks to this Alvotech narrative.

Next Steps

Mixed signals on Alvotech so far. If you want to move fast and build your own take, start with the balance of 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Alvotech?

Do not stop with Alvotech. Use the Simply Wall Street Screener to quickly surface fresh opportunities that match your style before the crowd pays attention.

• Target potential mispricings by scanning a curated set of 29 high quality undervalued stocks that combine quality fundamentals with appealing entry points.
• Strengthen your defensive side by reviewing a list of solid balance sheet and fundamentals (25 results) that can help anchor your portfolio when conditions get tougher.
• Get ahead of the market by hunting through 20 high quality undiscovered gems where strong fundamentals have yet to attract broad attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com